MET and breast carcinoma: It has been reported by Gurrapu et al. that PLXNB2 promotes breast cancer cell proliferation through the RhoA and MAPK signaling pathways51, which appears to be context-dependent and influenced by the expression levels of co-receptors such as MET and ErbB2.